IJCTM/
Articles/
2508001049
  • Open Access
  • Original Research Articles

A Decreasing Estimated Glucose Disposal Rate Is Associated with an Increase in Biomarkers of Inflammation

  • Ishwarlal Jialal 1, *, †,   
  • Beverley Adams-Huet 2

Received: 21 Jul 2025 | Accepted: 29 Jul 2025 | Published: 09 Oct 2025

Abstract

The estimated glucose disposal rate (eGDR) is a validated measure of insulin resistance. Also, it predicts Metabolic Syndrome (MetS), diabetic microvascular and macrovascular complications, atherosclerotic cardiovascular disease (ASCVD) and mortality. However, mechanistic insights examining the relationship between eGDR and the above sequela are scanty. Accordingly, we investigated the relationship between the eGDR and a detailed repertoire of biomarkers of inflammation, oxidative stress, and adipokine dysregulation in a cohort (n = 78) comprising nascent MetS without the confounding of type 2 diabetes mellitus(T2DM), ASCVD, smoking, chronic inflammation, and hypolipidemic drug therapy and matched controls using both tertiles of eGDR and correlations with relevant variables. Cardiometabolic features were significantly different across eGDR tertiles and correlated with eGDR. Receiver operating Characteristic (ROC) curve analysis revealed that eGDR was an excellent predictor of MetS with an area under the curve of 0.89. Also, CRP, IL-6, endotoxin, chemerin, leptin, retinol-binding protein-4 (RBP-4) and monocyte TLR-2 abundance and activity were significantly higher in tertile 1 versus tertile 3 of eGDR and all except RBP-4 correlated with eGDR. Biomarkers of oxidative stress were not significant over tertiles of eGDR. In conclusion, in patients without the confounding of T2DM, ASCVD, smoking, macro-inflammation and lipid therapy, the eGDR is an excellent predictor of MetS. It appears based on our findings that a pro-inflammatory state evidenced collectively by increases in hsCRP, endotoxin, chemerin, leptin, RBP-4, IL-6, TLR-2 abundance and activity, could be advanced as a mediating mechanism explaining the increased risk for diabetic complications and ASCVD.

References 

  • 1.
    Reaven, G.M. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu. Rev. Med. 1993, 44, 121–131.
  • 2.
    DeFronzo, R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia 2010, 53, 1270–1287. https://doi.org/10.1007/s00125-010-1684-1.
  • 3.
    Ormazabal, V.; Nair, S.; Elfeky, O.; et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018, 17, 122. https://doi.org/10.1186/s12933-018-0762-4.
  • 4.
    Caturano, A.; Vetrano, E.; Galiero, R.; et al. Advances in the Insulin-Heart Axis: Current Therapies and Future Directions. Int. J. Mol. Sci. 2024, 25, 10173. https://doi.org/10.3390/ijms251810173.
  • 5.
    Wallace, T.M.; Levy, J.C.; Matthews, D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27, 1487–1495. https://doi.org/10.2337/diacare.27.6.1487.
  • 6.
    Guerrero-Romero, F.; Simental-Mendía, L.E.; González-Ortiz, M.; et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J. Clin. Endocrinol. Metab. 2010, 95, 3347–3351. https://doi.org/10.1210/jc.2010-0288.
  • 7.
    Gounden, V.; Devaraj, S.; Jialal, I. The role of the triglyceride-glucose index as a biomarker of cardio-metabolic syndromes. Lipids Health Dis. 2024, 23, 416. https://doi.org/10.1186/s12944-024-02412-6.
  • 8.
    Williams, K.V.; Erbey, J.R.; Becker, D.; et al. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 2000, 49, 626–632. https://doi.org/10.2337/diabetes.49.4.626.
  • 9.
    Zabala, A.; Darsalia, V.; Lind, M.; et al. Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: A nationwide cohort study. Cardiovasc. Diabetol. 2021, 20, 202. https://doi.org/10.1186/s12933-021-01394-4.
  • 10.
    Epstein, E.J.; Osman, J.L.; Cohen, H.W.; et al. Use of the Estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 2013, 36, 2280–2285. https://doi.org/10.2337/dc12-1693.
  • 11.
    Chillarón, J.J.; Goday, A.; Flores-Le-Roux, J.A.; et al. Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2009, 94, 3530–3534. https://doi.org/10.1210/jc.2009-0960.
  • 12.
    Bahrami Hezaveh, E.; Hashemi, R.; Noorafrooz, M.; et al. Estimated Glucose Disposal Rate: A Potential Determinant for Microvascular and Macrovascular Complications in Type 2 Diabetes. Endocrinol. Diabetes Metab. 2025, 8, e70037. https://doi.org/10.1002/edm2.70037.
  • 13.
    Nyström, T.; Holzmann, M.J.; Eliasson, B.; et al. Estimated glucose disposal rate and long-term survival in type 2 diabetes after coronary artery bypass grafting. Heart Vessel. 2017, 32, 269–278. https://doi.org/10.1007/s00380-016-0875-1.
  • 14.
    Guo, L.; Zhang, J.; An, R.; et al. The role of estimated glucose disposal rate in predicting cardiovascular risk among general and diabetes mellitus population: A systematic review and meta-analysis. BMC Med. 2025, 23, 234. https://doi.org/10.1186/s12916-025-04064-4.
  • 15.
    Tao, S.; Yu, L.; Li, J.; et al. Insulin resistance quantified by estimated glucose disposal rate predicts cardiovascular disease incidence: A nationwide prospective cohort study. Cardiovasc. Diabetol. 2025, 24, 161. https://doi.org/10.1186/s12933-025-02672-1.
  • 16.
    Chen, X.; Li, A.; Ma, Q. Association of estimated glucose disposal rate with metabolic syndrome prevalence and mortality risks: A population-based study. Cardiovasc. Diabetol. 2025, 24, 38. https://doi.org/10.1186/s12933-025-02599-7.
  • 17.
    Bremer, A.A.; Devaraj, S.; Afify, A.; et al. Adipose tissue dysregulation in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2011, 96, E1782–E1788.
  • 18.
    Jialal, I.; Huet, B.A.; Kaur, H.; et al. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012, 35, 900–904.
  • 19.
    Jialal, I.; Devaraj, S.; Adams-Huet, B.; et al. Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. J. Clin. Endocrinol. Metab. 2012, 97, E1844–E1850.
  • 20.
    Jialal, I.; Devaraj, S.; Kaur, H.; et al. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J. Clin. Endocrinol. Metab. 2013, 98, E514–E517.
  • 21.
    Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112, 2735–2752.
  • 22.
    Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute: American Heart Association: World Heart Federation; International Atherosclerosis Society; and International Association for the study of Obesity. Circulation 2009, 120, 1640–1645.
  • 23.
    Jialal, I.; Adams-Huet, B.; Pahwa, R. Selective increase in monocyte p38 mitogen-activated protein kinase activity in metabolic syndrome. Diab Vasc. Dis. Res. 2016, 13, 93–96.
  • 24.
    Adams-Huet, B.; Devaraj, S.; Siegel, D.; et al. Increased adipose tissue insulin resistance in metabolic syndrome: Relationship to circulating adipokines. Metab. Syndr. Relat. Disord. 2014, 12, 503–508.
  • 25.
    Adams-Huet, B.; Zubirán, R.; Remaley, A.T.; et al. The triglyceride-glucose index is superior to homeostasis model assessment of insulin resistance in predicting metabolic syndrome in an adult population in the United States. J. Clin. Lipidol. 2024, 18, e518–e524. https://doi.org/10.1016/j.jacl.2024.04.130.
  • 26.
    Jialal, I.; Kaur, H.; Devaraj, S. Toll-like receptor status in obesity and metabolic syndrome: A translational perspective. J. Clin. Endocrinol. Metab. 2014, 99, 39–48.
  • 27.
    Adams-Huet, B.; Jialal, I. Correlates of Insulin Resistance in Nascent Metabolic Syndrome. Clin. Med. Insights Endocrinol. Diabetes 2023, 16, 11795514231168279. https://doi.org/10.1177/11795514231168279.
  • 28.
    Adams-Huet, B.; Jialal, I. An Increasing Triglyceride-Glucose Index Is Associated with a Pro-Inflammatory and Pro-Oxidant Phenotype. J. Clin. Med. 2024, 13, 3941. https://doi.org/10.3390/jcm13133941.
  • 29.
    Saraheimo, M.; Teppo, A.M.; Forsblom, C.; et al. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia. 2003, 46, 1402–1407. https://doi.org/10.1007/s00125-003-1194-5.
  • 30.
    Llauradó, G.; Gallart, L.; Tirado, R.; et al. Insulin resistance, low-grade inflammation and type 1 diabetes mellitus. Acta Diabetol. 2012, 49, 33–39. https://doi.org/10.1007/s00592-011-0257-1.
  • 31.
    Ferreira-Hermosillo, A.; Molina-Ayala, M.; Ramírez-Rentería, C.; et al. Inflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 Diabetes. J. Diabetes Res. 2015, 2015, 972073. https://doi.org/10.1155/2015/972073.
  • 32.
    Xing, D.; Xu, J.; Weng, X.; et al. Correlation between estimated glucose disposal rate, insulin resistance, and cardiovascular mortality among individuals with metabolic syndrome: A population-based analysis, evidence from NHANES 1999–2018. Diabetol. Metab. Syndr. 2025, 17, 11. https://doi.org/10.1186/s13098-024-01574-8.
  • 33.
    Xu, L.; Ma, J.; Xu, Y. The effects of estimated glucose disposal rate and high sensitivity C-reactive protein on risk of incident cardiovascular diseases in middle-aged and elderly Chinese adults: A nationwide prospective cohort study. Lipids Health Dis. 2025, 24, 234. https://doi.org/10.1186/s12944-025-02653-z.
Share this article:
Download PDF
DOI
10.53941/ijctm.2025.1000027
Issue
Volume 1, Issue 4
How to Cite
Jialal, I.; Adams-Huet, B. A Decreasing Estimated Glucose Disposal Rate Is Associated with an Increase in Biomarkers of Inflammation. International Journal of Clinical and Translational Medicine 2025, 1 (4), 6. https://doi.org/10.53941/ijctm.2025.1000027.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2025 by the authors.